These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 5854944)

  • 21. Two unusual cases of cutaneous leishmaniasis responding to pentavalent antimonials.
    Vermeer BJ; van der Kaay HJ
    Acta Leiden; 1983 Dec; 51():31-5. PubMed ID: 6089490
    [No Abstract]   [Full Text] [Related]  

  • 22. [Electrocardiographic changes during antibilharzia treatments. Antimonies and nitrathiazoles].
    Labrousse J; Gentilini M; Berthier Y; Morin J; Domart A
    Coeur Med Interne; 1967 Apr; 6(2):153-60. PubMed ID: 5618965
    [No Abstract]   [Full Text] [Related]  

  • 23. [Therapeutic evaluation of antimony and sodium dimercaptosuccinate in the treatment of schistosomiasis mansoni].
    Siqueira MW; Huggins D
    Rev Bras Med; 1967 Feb; 24(2):97-9. PubMed ID: 5604907
    [No Abstract]   [Full Text] [Related]  

  • 24. Treatment of paediatric visceral leishmaniasis: amphotericin B or pentavalent antimony compounds?
    Kafetzis DA; Velissariou IM; Stabouli S; Mavrikou M; Delis D; Liapi G
    Int J Antimicrob Agents; 2005 Jan; 25(1):26-30. PubMed ID: 15620822
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Resistance to antimony and treatment failure in human Leishmania (Viannia) infection.
    Rojas R; Valderrama L; Valderrama M; Varona MX; Ouellette M; Saravia NG
    J Infect Dis; 2006 May; 193(10):1375-83. PubMed ID: 16619185
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular mechanisms of antimony resistance in Leishmania.
    Ashutosh ; Sundar S; Goyal N
    J Med Microbiol; 2007 Feb; 56(Pt 2):143-53. PubMed ID: 17244793
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of fluconazole on the pharmacokinetics and pharmacodynamics of antimony in cutaneous leishmaniasis-infected hamsters.
    Alnaim L; Abou Alsoud N; Zaghloul I; Al-Jaser M
    Int J Antimicrob Agents; 2007 Jun; 29(6):728-32. PubMed ID: 17369029
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [What did prove useful in the treatment of leishmaniasis].
    Kurban A
    Hautarzt; 1973 Jun; 24(6):271. PubMed ID: 4723879
    [No Abstract]   [Full Text] [Related]  

  • 29. [TOXIC EFFECT OF TRIVALENT ANTIMONY AND MIRACIL D PREPARATIONS ON CARDIOVASCULAR SYSTEM DURING THERAPY OF SCHISTOSOMIASIS PATIENTS].
    ASLAMAZOV EG; MIKHAILOV AA
    Sov Med; 1963 Jun; 27():65-70. PubMed ID: 14069291
    [No Abstract]   [Full Text] [Related]  

  • 30. Electrocardiographic changes occurring during the treatment with fuadin solution.
    BEASER SB; RODRIGUEZ MOLINA R
    Am Heart J; 1946 Nov; 32(5):634-44. PubMed ID: 20274722
    [No Abstract]   [Full Text] [Related]  

  • 31. Comparison of generic to branded pentavalent antimony for treatment of new world cutaneous leishmaniasis.
    Soto J; Valda-Rodriquez L; Toledo J; Vera-Navarro L; Luz M; Monasterios-Torrico H; Vega J; Berman J
    Am J Trop Med Hyg; 2004 Nov; 71(5):577-81. PubMed ID: 15569787
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Changes in the electrocardiographic (ECG) tracings under the influence of treatment with nitrothiazolyl-imidazolidinone (Ciba 32644-Ba)].
    Lambert CR; Imhof PR; Attar HJ
    Acta Trop Suppl; 1966; 9():269-74. PubMed ID: 5219869
    [No Abstract]   [Full Text] [Related]  

  • 33. Comparative antimony disposition following administration of tartar emetic and sodium antimony dimercaptosuccinate (Astiban) to hamsters infected with Schistosoma mansoni.
    Schulert AR; Girgis NI; Girgis GR; Farid Z; McConnell E
    East Afr Med J; 1967 Jan; 44(1):1-8. PubMed ID: 6038793
    [No Abstract]   [Full Text] [Related]  

  • 34. The severe toxic reactions of antimony treatment of bilharziasis.
    el-Halawani AA
    Bull Endem Dis (Baghdad); 1968 Nov; 10(1):123-33. PubMed ID: 4340593
    [No Abstract]   [Full Text] [Related]  

  • 35. Comparison of the chemotherapeutic potencies of 4 antimonial drugs.
    Khayyal MT
    Bull World Health Organ; 1969; 40(6):959-63. PubMed ID: 5307606
    [No Abstract]   [Full Text] [Related]  

  • 36. Interleukin 10 receptor blockade--pentavalent antimony treatment in experimental visceral leishmaniasis.
    Murray HW
    Acta Trop; 2005 Mar; 93(3):295-301. PubMed ID: 15716043
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Myocardial involvement in antimonial therapy: a case report of acute antimony poisoning with serial ECG changes.
    Sapire DW; Silverman NH
    S Afr Med J; 1970 Aug; 44(33):948-50. PubMed ID: 5453172
    [No Abstract]   [Full Text] [Related]  

  • 38. Suppressive management of urinary schistosomiasis with antimony dimercaptosuccinate (TWSb) in Ghana.
    Wolfe MS; Quansah FO; Agbemadzo F
    J Trop Med Hyg; 1966 Oct; 69(10):217-23. PubMed ID: 5929012
    [No Abstract]   [Full Text] [Related]  

  • 39. Short communication: The cost-effectiveness of cutaneous leishmaniasis patient management during an epidemic in Chaparral, Colombia in 2004.
    Vega JC; Sanchez BF; Montero LM; Montaña R; Del Pilar Mahecha M; Dueñes B; Baron AR; Reithinger R
    Trop Med Int Health; 2007 Dec; 12(12):1540-4. PubMed ID: 18076562
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Miltefosine: oral treatment of leishmaniasis.
    Soto J; Soto P
    Expert Rev Anti Infect Ther; 2006 Apr; 4(2):177-85. PubMed ID: 16597200
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.